Podcasts about Health Canada

Dr. Chris Labos, cardiologist with a degree in epidemiology and a regular contributor on CJAD 800. You can hear him every Sunday on Weekends with Joanne Vrakas at 7:20 a.m.

Lecanemab is a new drug that's being made available in Canada to slow the early stage of Alzheimer's disease. We speak to Linda McMaster, who is on the waitlist to receive it. And Drs Sandra Cohen and Samir Sinha about the efficacy, cost and reality of how this new drug fits in with the wider Alzheimer's care environment in Canada today.

Greg Brady spoke to Dr. Colin Carrie, health specialist and former Conservative MP for Oshawa - Parliamentary Secretary of Health in the Harper government about Health Canada approves 1st drug to slow Alzheimer's disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this flavorful new episode of The Food Professor Podcast—presented by Caddle—Michael LeBlanc and Dr. Sylvain Charlebois serve up an inspiring conversation with Rob Sengotta, chef and co-founder of Von Slick's Finishing Touch, the award-winning Manitoba-based producer of gourmet compound butters.The InterviewRob takes listeners behind the scenes of his chef-to-entrepreneur journey—from fine-dining kitchens in London and France to building a small-batch butter business on the prairies. He shares how curiosity and culinary discipline led to Von Slick's signature push-tube packaging and eight imaginative flavours, including garlic confit, roasted red pepper, mushroom duxelle, and cowboy butter.Listeners learn how Rob and partner Landon Craker turned a spark of an idea into a thriving Western Canadian brand by mastering distribution, leveraging farmers' markets, and staying creative on social media. Rob reflects on his early appearance on Dragon's Den, the lessons learned about timing and valuation, and the advantages of remaining proudly local. He also reveals new restaurant-format products, growing online sales nationwide, and why Canadians' appetite for supporting homegrown brands continues to expand.The NewsIn the first half, Sylvain reports live from Medellín, Colombia, where he's attending an international conference on rural food economies. He offers a fascinating window into Colombia's agricultural transformation—how coffee and cocoa remain vital exports and how farmers are striving to move beyond decades of narcotics-driven instability.Back in Canada, Michael and Sylvain unpack the latest headlines:CFIA factory inspections and the urgent need for transparency;Health Canada's cloned-meat consultations, why silent science can backfire, and the parallels to GMO controversies;Parliamentary hearings on the grocery code of conduct and why supplier–retailer trust still drives price volatility;Bank of Canada's rate decision, its implications for restaurants and food-service recovery; andThere is a growing debate over adopting a U.S.-style SNAP food-assistance program in Canada.This episode blends global perspective, policy insight, and entrepreneurial inspiration—proving again that from farm to fork, the Canadian food economy is as complex as it is delicious. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Dr. Sharon Cohen is the medical director at Toronto Memory Program and an investigator in the drug's clinical trials. Learn more about your ad choices. Visit megaphone.fm/adchoices

Greg Brady spoke to Dr. Colin Carrie, health specialist and former Conservative MP for Oshawa - Parliamentary Secretary of Health in the Harper government about Health Canada approves 1st drug to slow Alzheimer's disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

Alternative medicine is nothing new.Although it can be risky and sometimes harmful, people with chronic pain or debilitating health complications are usually open to seeing what other treatment options can ease their pain - even if it's illegal and very much inaccessible. A recent North American study found that one supervised dose of lysergic acid diethylamide or LSD - commonly known as acid - eased anxiety symptoms for several months. But the research on psychedelics being used to treat mental health issues is still very much in its premature phase, with nothing conclusive or substantial enough to enact changes from Health Canada.Host Maria Kestane speaks to Dr. Roger McIntyre, professor of psychiatry, and professor of pharmacology and toxicology at the University of Toronto to discuss the potential that psychedelics hold in the future of health and wellness, and whether or not it's suitable for everyone. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Health Canada has authorized a drug shown to slow the progression of Alzheimer's disease. The Greater Victoria Harbour Authority says it's abandoning plans to install shore power for cruise ships at Ogden Point — a project long touted as a way to cut greenhouse gas emissions and improve air quality in the James Bay neighbourhood. In honey bee colonies, worker bees will overthrow a failing queen in a carefully coordinated process known as supersedure. Recent research from the University of British Columbia sheds light on why these ‘royal revolts' happen and how viral infections in queens can trigger them. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Daily Value, we examine Consumer Reports' October 2025 findings on lead in protein powders. The investigation tested 23 products and found that more than two-thirds exceeded the organization's internal lead safety threshold. We discuss what those results mean in biological terms, how regulatory limits differ between the FDA, EFSA, and Health Canada, and how supplement exposure compares to everyday dietary intake.00:00 Introduction00:08 Consumer Reports Investigation Finds Lead in Protein Powders01:07 Understanding Lead Contamination in Protein Powders03:00 Health Implications of Lead Exposure06:41 Regulatory Standards and Safety Thresholds09:30 Comparing Lead Intake from Food and Supplements15:56 Practical Advice and Final Thoughtshttps://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2010.1570https://www.fda.gov/food/fda-total-diet-study-tds/fda-total-diet-study-tds-resultshttps://www.consumerreports.org/lead/protein-powders-and-shakes-contain-high-levels-of-lead-a4206364640/https://wwwn.cdc.gov/Tsp/ToxProfiles/ToxProfiles.aspx?id=96&tid=22

Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive's Stephen Gunnion about first-in-human data for the company's targeted hyperthermia therapy (THT), showing significant tumor response in patients with late-stage melanoma. The early feasibility study involved ten patients who had not responded to standard immunotherapy. Regan said, “We were able to get a response in eight out of ten of them, of which six were complete responses.” Biopsies conducted within two weeks confirmed that the treated tumors no longer contained melanoma cells. THT uses nanoparticles injected into tumors and activated by a near-infrared laser. The laser energy creates heat at 45°C, selectively killing cancer cells without harming healthy tissue. The process also stimulates the immune system, which Regan said was a critical component: “We're really helping to fire up the immune system to fight the cancer on its own.” Sona now plans to move into a Canadian clinical trial, pending Health Canada approval. Regan emphasized that these results could extend beyond melanoma, potentially benefiting other solid tumors resistant to immunotherapy. Investors can expect updates on histological data analysis and direction for broader clinical applications. Sona has already submitted an application to Health Canada and hopes to engage with the regulator soon. #SonaNanotech #CancerTreatment #TargetedHyperthermia #Melanoma #BiotechNews #Immunotherapy #ClinicalTrials #Oncology #MedicalInnovation #HealthcareTech

This week on Thoughts Off The Stem, we're lighting up the truth about THC potency fraud in the legal cannabis market. Some companies are intentionally mislabelling THC levels, and Health Canada's response? Painfully slow.We'll dig into why regulators ignored industry insiders' warnings, how their “public health first” stance doesn't match their actions, and why the 10mg edible cap might actually be part of the problem.Could more realistic potency ranges stop shady labeling and give consumers what they really paid for? Let's talk corporate greed, government red tape, and the real impact on cannabis culture.Like, Share, Subscribe, leave a Comment and visit Tots420.comYou can read the article referenced on the show here:https://stratcann.com/news/two-potluck-chillows-products-recalled-in-ontario-due-to-excessive-variability-and-exceeding-10-mg-thc-limit/THC label lies,Health Canada controversy,cannabis industry Canada,cannabis mislabelling,THC potency,cannabis comedy podcast,Thoughts Off The Stem,Justin Barone,weed podcast,cannabis culture,cannabis podcast Canada,cannabis regulation,edible THC limit,legal weed Canada,cannabis news,weed humor,cannabis industry expose,THC testing,cannabis consumers,Health Canada,funny cannabis podcast,insight,unfiltered,real talk,comedy podcast,cannabis education

Shawn Buckley is a Canadian lawyer specializing in constitutional, criminal, and regulatory law. He founded Buckley & Company Law in 1995, focusing on Health Canada litigation, particularly under the Food and Drugs Act concerning natural health products (NHPs). Shawn is also the founder of the Natural Law Alliance (a non-profit advocating for health freedoms) and a founding member and lead counsel for the National Citizens Inquiry.Teresa Buckley works alongside Shawn in advocacy efforts, particularly through the Natural Health Product Protection Association (NHPPA). She is involved in public education and grassroots campaigns to safeguard access to herbs, supplements, and homeopathic remedies. Together they have embarked on The Health Charter Tour: A cross-Canada campaign to rally public support for a "Health Charter" – a proposed framework to constitutionally enshrine rights to natural health choices.Tickets to Cornerstone Forum 26': https://www.showpass.com/cornerstone26/Tickets to the Mashspiel:https://www.showpass.com/mashspiel/Silver Gold Bull Links:Website: https://silvergoldbull.ca/Email: SNP@silvergoldbull.comText Grahame: (587) 441-9100Bow Valley Credit UnionBitcoin: www.bowvalleycu.com/en/personal/investing-wealth/bitcoin-gatewayEmail: welcome@BowValleycu.com Use the code “SNP” on all ordersProphet River Links:Website: store.prophetriver.com/Email: SNP@prophetriver.comGet your voice heard: Text Shaun 587-217-8500

PharmAla Biotech Holdings CEO Nicholas Kadysh joined Steve Darling from Proactive's OTC studio in New York City to discuss the company's ongoing progress in clinical MDMA supply and development. Kadysh highlighted that PharmAla was founded as a dedicated MDMA company, and today operates as one of the world's leading producers and suppliers of MDMA for clinical use, particularly in Canada and Australia. In addition to supplying MDMA for patient treatments and clinical trials, the company is developing novel analogs for a range of medical conditions. The company holds a controlled substances license from Health Canada, enabling legal manufacture and supply of MDMA. PharmAla collaborates with leading academic and government institutions, including Harvard, Yale, Johns Hopkins, and the University of Arkansas. Kadysh noted the company's involvement in a new Canadian study funded by the Canadian Institutes for Health Research, which explores MDMA for neuropathic pain, with PharmAla supplying the compound. The company is also advancing MDMA analogs targeting social anxiety and brain trauma, including post-stroke recovery and traumatic brain injury. “We view part of our mission as making sure actual patients get the medication, not just clinical researchers,” Kadysh emphasized, underscoring the company's commitment to real-world patient access. The interview also highlighted PharmAla's collaboration with U.S. government agencies, including the Veterans Affairs Administration and Defense Health Agency, for military-related clinical trials. #proactiveinvestors #pharmalabiotechholdings #cse #mdma #otc #mdxxf #PharmAlaBiotech #MDMAResearch #BiotechNews #ClinicalTrials #MentalHealthInnovation #NeuropathicPain #DrugDevelopment #ControlledSubstances #HealthCanada #VeteransHealth #BrainTraumaTreatment #SocialAnxietyRelief

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

The battle for Canada's health freedom is on.Health Canada's Self-Care Framework threatens to eliminate most of the natural health products Canadians rely on — and the people are fighting back.In this explosive episode of Truehope Cast, we join the Health Charter Tour: Day 4 — the nationwide movement led by constitutional lawyer Shawn Buckley and Truehope founder Anthony Stephan — to expose Health Canada's insidious plan and ignite a new wave of awareness across the country.Discover what's really at stake, how the Charter of Health Freedom could protect your right to natural healing, and why Canadians everywhere are standing together to stop government overreach once and for all.

Key Points Seadon experienced his first Grand mal seizure at age three, lasting over 20 minutes, with medical staff initially believing he would suffer brain damage from the prolonged episode.Medical professionals prescribed benzodiazepines which reduced seizure frequency and severity but required continuous dose increases as Seadon continued having seizures for four years.By age seven, Seadon was taking the maximum benzodiazepine dose equivalent to an 18-19 year old but still experiencing seizures, prompting consultation with alternative neurologists.Memory impairment was identified as a significant side effect of the benzodiazepine medication, causing Seadon to forget basic daily tasks and potentially creating permanent cognitive damage.Research into natural alternatives consistently pointed to cannabis as the only viable option, though specific dosing and cultivation information was extremely limited at the time.Pharmaceutical shortage crisis forced an immediate decision when Seadon's medication became unavailable, with Health Canada offering three replacement drugs including ones with suicide risk and irreversible liver damage.Cannabis treatment began with a one-to-one CBD-THC tincture obtained from a veteran's prescription, starting with low doses while simultaneously weaning off benzodiazepines.Seadon achieved complete seizure freedom for 11 years using a customized cannabis regimen of 20-to-1 CBD-THC ratio during daytime and 1-to-1 ratio at nighttime.Memory function significantly improved after transitioning from pharmaceuticals to cannabis, contradicting common misconceptions about cannabis effects on developing brains.Legal prescription acquisition took over 18 months due to reluctance from healthcare providers to treat pediatric patients, eventually obtained through a questionable cannabis clinic charging $2,000 annually.Medical establishment resistance continued even after successful treatment, with neurologists refusing prescription renewals despite 100% seizure control and excluding Seadon from cannabis epilepsy studies.Family doctor refused to write cannabis prescriptions despite supporting the treatment results, ultimately involving legal counsel when challenged about patient rights violations.EduCanNation nonprofit was founded in 2020 to standardize cannabis education and provide proper guidance to patients, addressing the lack of reliable information and support systems.Organization connects certified cannabis educators who are primarily former patients, aiming to share evidence-based knowledge and prevent others from experiencing similar healthcare navigation challenges. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The European Union recently banned the sale and use of Trimethylbenzoyl Diphenylphosphine Oxide - also known as TPO - for its alleged reproductive toxicant qualities. Most gel nail polishes contain TPO, as it's the key ingredient to ensure a shiny finish after hardening following exposure to UV light.However, Canada has yet to take any similar action, considering its risk-based model for product regulation. But if the writing is on the wall about TPO's dangers, what is stopping Health Canada from taking a proactive stance on reproductive safety?Host Maria Kestane speaks to Miriam Diamond, a professor in the department of earth sciences & The School of the Environment at the University of Toronto to discuss the different regulatory approaches between the EU and Canada, and how Canadians can make their own informed choices on the treatments they pay for. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Last Monday, the Trump administration linked Tylenol to autism and warned against pregnant women taking it — Health Canada says there is no conclusive evidence and continues to recommend acetaminophen to treat fever and pain during pregnancy. This is not the first time U.S. President Trump or Health Secretary Robert F. Kennedy Jr. have made controversial remarks on autism and what causes it. And some advocates and scientists are concerned about the wider impact this could have. Today, developmental pediatrician Dr. Melanie Penner joins the show to help us unpack the growing fixation on autism, why unproven links to its cause continue to resurface, and what we should be focusing on instead. Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On today's episode of The Candice Malcolm Show, Candice highlights Ottawa's pattern of putting politics and ideology ahead of evidence and common sense, and how the legacy media runs cover every step of the way. The National Telegraph founder Wyatt Claypool joins the show to discuss the Supreme Court's decision to pause the Canadian Food Inspection Agency's order to cull more than 400 ostriches in British Columbia. Despite the birds recovering from avian flu, the agency pushed ahead anyway, sparking protests, arrests, and outrage before the court stepped in. Next, Candice and Wyatt discuss Health Canada's decision to contradict President Trump and RFK Jr. on warnings about Tylenol use during pregnancy. Instead of addressing years of studies pointing to potential risks, officials sided with Big Pharma and dismissed the concerns simply to spite Trump. They also examine how Liberals continue funnelling money to the Canadian Anti-Hate Network, an activist group with Antifa ties, even after President Trump signed an executive order designating Antifa a domestic terrorist organization. Finally, Candice is joined by RockLinc CEO Jonathan Wellum to examine Ottawa's looming “mega deficit.” With Carney preparing to spend billions more while capital and jobs flee, Wellum warns Canada is falling further behind as the U.S. reindustrializes under Trump. Learn more about your ad choices. Visit megaphone.fm/adchoices

Health Canada is one of the global health organizations pushing back against U.S. President Donald Trump's adminitration's claims that the use of acetaminophen during pregnancy is linked to autism. We're joined by a scientific researcher, and a parent with lived experience with autism to take audience calls.

Send us a text“Doctor” Trump is at it again.This week, the U.S. president warned pregnant women to limit their use of acetaminophen — the active ingredient in Tylenol — because of unsubstantiated links to autism. “Fight like hell not to take it,” was the president's message.Experts around the world were quick to counter Trump's medical advice, insisting there is no evidence linking autism in children to the use of Tylenol by pregnant women.Health Canada issued a public advisory reiterating that the over-the-counter drug has “been used safely by millions of Canadians for decades, including during pregnancy and while breastfeeding,” while the Society of Obstetricians and Gynaecologists of Canada (SOGC) called the autism link “weak” and “consistently refuted by scientific and regulatory bodies.”“In an age of growing misinformation and disinformation, the SOGC strongly urges all Canadians to ensure decisions about their health care is guided by evidence-based science and clinical expertise,” the society said.Joining us on Closer Look tonight to discuss Trump's comments is Dr. Darine El-Chaâr, a maternal fetal medicine physician at The Ottawa Hospital and an associate professor at the University of Ottawa.Hosted by Village Media's Michael Friscolanti and Scott Sexsmith, and produced by Derek Turner, Closer Look is a new daily podcast that goes way beyond the headlines with insightful, in-depth conversations featuring our reporters and editors, leading experts, key stakeholders and big newsmakers.Fresh episodes drop every Monday to Friday at 7 p.m. right in your local news feed — and on the show's dedicated website: closerlookpodcast.ca. Of course, you can also find us wherever you get your favourite podcasts.Want to be the first to know when a new episode lands? Sign up for our free nightly newsletter, which delivers the latest Closer Look straight to your email inbox. You can also subscribe to our YouTube channel or follow us on X, Instagram, Facebook and TikTok.Have something to say? Please reach out. Our email address is closerlook@villagemedia.ca.

A flood warning is in effect after torrential rains hit much of Windsor-Essex, a Windsor grocery store fire is considered suspicious, and Health Canada says pregnant women can take Tylenol. All the evening headlines on the go.

CleanGo Innovations Inc. (OTCQB: CLGOF) is an FDA and Health Canada approved manufacturer of a suite of green, non-toxic, and biodegradable cleaning products for industrial, commercial, and consumer markets. Anthony Sarvucci, CEO and President of CleanGo Innovations, joins us to explore how the company's use of clean, dual-purpose ingredients—both eco-friendly and disinfecting—is redefining industry standards and giving them a competitive edge. View Podcast Transcript

Disease-modifying therapies are the cornerstone of MS treatment, but they're not the only piece of the puzzle. Beyond prescription medications, self-care that includes making healthy lifestyle choices can significantly improve your quality of life with MS.  Julie Polisena knows this firsthand. Julie lives with MS, and in a recent blog post, she shared a comprehensive list of the lifestyle changes that have improved her quality of life with MS. Julie joins us today to discuss some of the most impactful changes you can make to start your own journey toward better health and wellness.   We're also diving into the science behind some of the most talked-about diets for MS. We're breaking down the research on the Mediterranean diet, the Keto diet, the Wahls Diet, the Swank Diet, a gluten-free diet, and intermittent fasting, giving you an overview of the studies that have measured their impact on MS. We're discussing the latest developments in the ongoing scrutiny of pharmacy benefit managers (PBMs). There's significant pending legal action and a congressional investigation targeting PBMs, the powerful and secretive middlemen in the prescription drug supply chain. And we'll tell you how they've profited at the expense of millions of people with chronic illnesses, including people living with MS. We'll tell you about a clinical trial that's testing an injectable formulation of Briumvi. You'll hear about a promising new strategy for myelin repair. And we'll remind you about a warning from the FDA and Health Canada about glatiramer acetate (Copaxone). We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A DIY approach to improving your MS journey  :22 A roundup of studies that focused on popular diets for people with MS  1:53 Congress and the FTC have pharmacy benefit managers in their sites  7:32 TG Therapeutics is testing an injectable form of Briumvi   9:32 A research team has developed a novel remyelination strategy  11:03 A warning about glatiramer acetate has been issued  14:08 Julie Polisena discusses lifestyle changes that can make a difference in your quality of life  16:58 Share this episode  33:24 Next week's episode   33:43 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/420 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy READ: Small Changes, Big Impact: Managing My MS Through Lifestyle Changes https://mscanada.ca/find-support/blog/small-changes-big-impact-managing-my-ms-through-lifestyle-change STUDY: The Role of Nutrition and Physical Activity in Modulating Disease Progression and Quality of Life in Multiple Sclerosis https://mdpi.com/2072-6643/17/16/2713 STUDY: Transient Gene Melting Governs the Timing of Oligodendrocyte Maturation https://sciencedirect.com/science/article/abs/pii/S009286742500861X REVIEW: Copaxone, Glatopa (Glatiramer Acetate) FDA Drug Safety Communication https://www.fda.gov/safety/medical-product-safety-information/copaxone-glatopa-glatiramer-acetate-drug-safety-communication-fda-adds-boxed-warning-about-rare JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 420 Guest: Julie Polisena Privacy Policy

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

Liberty Dispatch ~ September 05, 2025 In this episode of Liberty Dispatch, hosts Andrew DeBartolo and Matthew Hallick talk about how our statist, secular "humanist” society has manifested its true identity, namely, that it is actually a demonic death cult, which the most recent Canadian news makes evident. For full access to all our content, including the extended interviews, become a paid subscriber at: ldcanada.substack.com; Opening & Intro (00:00-01:03) Welcome & Introduction (01:03-07:53) Segment 1 - Queer Terror-Lovers CANCEL Ottawa Pride (08:53-22:41):“Pride Parade cancelled after being halted by pro-Palestinian protesters” | CBC News: https://www.cbc.ca/news/canada/ottawa/pride-parade-cancelled-after-being-halted-by-pro-palestinian-protesters-1.5554689?cmp=newsletter_Evening%20Headlines%20from%20CBC%20News_1617_;“Pride Parade in Canada's capital canceled after disruption by Queers for Palestine” | The Post Millennial: https://thepostmillennial.com/pride-parade-in-canadas-capital-canceled-after-disruption-by-queers-for-palestine?utm_content=; Segment 2 - Conservatives Gain Momentum (24:16-35:11):“Abacus Data poll: Conservatives edge ahead as cost of living dominates and Trump fades” | Abacus Data: https://abacusdata.ca/abacus-data-poll-conservatives-edge-ahead-as-cost-of-living-dominates-and-trump-fades;“Canada to drop some of its retaliatory tariffs on the U.S.” | BBC News: https://www.bbc.co.uk/news/articles/c5yk9dqlvygo; Segment 3 - Canada is Cringe! (36:05-52:08):“Health Canada approves updated Pfizer/Moderna COVID-19 vaccines for fall” | CTV News: https://www.ctvnews.ca/health/article/health-canada-approves-updated-pfizer-moderna-covid-19-vaccines-for-fall;“Vancouver parents blocked from teaching kids to swim at public pools” | Vancouver Sun: https://vancouversun.com/news/vancouver-parents-blocked-teaching-kids-swim-public-pools. Conclusion & Outro (52:08 -59:33) SHOW SPONSORS:New Sponsor! Bitcoin Mentor: https://bitcoinmentor.io/aff/liberty Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/; SUBSCRIBE TO OUR SHOWS/CHANNELS: LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com ; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Liberty Dispatch ~ August 28, 2025 In this episode of Liberty Dispatch, hosts Andrew DeBartolo and Matthew Hallick talk about how Carney caving to Trump on tariffs to get back to trade talks is yet another example of how Canada is going full cringe, including destroying private property rights, punishing parents as criminals go free, and, yes, still pushing the jab. For full access to all our content, including the extended interviews, become a paid subscriber at: ldcanada.substack.com; Episode Resources: The Politics of Civil War | Ezra Institute: https://youtu.be/NFE-yBUnM2c;  Are We Headed for Civil War? - David Betz | Triggernometry: https://www.youtube.com/watch?v=3h49O0AGxx0;  Opening & Intro (00:00-01:03) Welcome & Introduction (01:03-07:53) Segment 1 - Queer Terror-Lovers CANCEL Ottawa Pride (08:53-22:41): “Pride Parade cancelled after being halted by pro-Palestinian protesters” | CBC News: https://www.cbc.ca/news/canada/ottawa/pride-parade-cancelled-after-being-halted-by-pro-palestinian-protesters-1.5554689?cmp=newsletter_Evening%20Headlines%20from%20CBC%20News_1617_; “Pride Parade in Canada's capital canceled after disruption by Queers for Palestine” | The Post Millennial: https://thepostmillennial.com/pride-parade-in-canadas-capital-canceled-after-disruption-by-queers-for-palestine?utm_content=; Segment 2 - Conservatives Gain Momentum (24:16-35:11): “Abacus Data poll: Conservatives edge ahead as cost of living dominates and Trump fades” | Abacus Data: https://abacusdata.ca/abacus-data-poll-conservatives-edge-ahead-as-cost-of-living-dominates-and-trump-fades; “Canada to drop some of its retaliatory tariffs on the U.S.” | BBC News: https://www.bbc.co.uk/news/articles/c5yk9dqlvygo; Segment 3 - Canada is Cringe! (36:05-52:08): “Health Canada approves updated Pfizer/Moderna COVID-19 vaccines for fall” | CTV News: https://www.ctvnews.ca/health/article/health-canada-approves-updated-pfizer-moderna-covid-19-vaccines-for-fall; “Vancouver parents blocked from teaching kids to swim at public pools” | Vancouver Sun: https://vancouversun.com/news/vancouver-parents-blocked-teaching-kids-swim-public-pools. Conclusion & Outro (52:08 -59:33) SHOW SPONSORS: New Sponsor! Bitcoin Mentor: https://bitcoinmentor.io/aff/liberty Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/; SUBSCRIBE TO OUR SHOWS/CHANNELS: LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com ; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD: Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Pfizer and Moderna's latest COVID-19 vaccines have been approved by Health Canada, and are expected to be rolled out in the coming weeks in advance of an expected wave this fall. Our weekly health contributor explains who should get them. (Krissy Holmes with Dr. Iris Gorfinkel)

In this episode we're finally spilling the tea on our community's most-requested single mushroom: maitake (Grifola frondosa), a.k.a. Hen of the Woods. Brandi and Dr. Des share why Eversio chose maitake for a standalone fruiting-body, hot-water extract capsule - and how it supports:- immune resilience- metabolic health (blood sugar + lipids)- women's hormonesYou'll hear the origin story, dosing decisions (hello, Health Canada monograph), cultivation nerdery, research highlights (PCOS + ovulation, insulin sensitivity), and why we're keeping the extract whole (not isolated fractions). We also gush about ergothioneine, the “longevity vitamin,” and how to pair maitake with our upcoming 5 Mushroom Blend.If you love this conversation, please subscribe, rate, and share it with someone who could use a little more radiant, resilient wellness in their life.TAKE THE QUIZ:If you're not sure where to begin on your mushroom wellness journey, take our Naturopathic Doctor curated Mushroom Wellness QUIZ to find your mushroom match.Use code PODCAST15 for 15% off your entire mushroom wellness order at: https://www.eversiowellness.com/discount/PODCAST15JOIN OUR COMMUNITY: Instagram@eversiowellness:https://www.instagram.com/eversiowellness/ YouTube @eversiowellness:www.youtube.com/@eversiowellness Pinterest @eversiowellness: https://ca.pinterest.com/eversiowellness/ TikTok @eversio_wellness: https://www.tiktok.com/@eversio_wellness Facebook @eversio_wellness: www.facebook.com/eversiowellnessltdAWESOME FREE THINGS:Mushrooms For Gut Health Quick Start Guide: https://www.eversiowellness.com/pages/free-constipation-quick-startMushroom Extract Recipe Collection: https://www.eversiowellness.com/pages/free-recipe-collectionMushroom Benefits Cheat Sheet: https://www.eversiowellness.com/pages/free-cheat-sheetMushroom Extract Breakfast Recipes Collection: https://www.eversiowellness.com/pages/free-breakfast-recipes-collectionMUSHROOM WELLNESS RESOURCES:Mushroom Wellness Blog: https://www.eversiowellness.com/blogs/newsMushroom Extract Recipe Page: https://www.eversiowellness.com/blogs/mushroom-recipesQuestions? Contact us here: https://www.eversiowellness.com/pages/contactSign up for our Emails or SMS to be the first to know about product drops, promos, mushroom wellness news! Email List: https://www.eversiowellness.com/pages/sign-up-for-emails SMS List: https://www.eversiowellness.com/pages/sign-up-for-sms Podcast Website: www.eversiowellness.com for detailed show notesPlease Rate or Share The Eversio Experience Podcast by clicking the 3 dots at the top of the podcast homepage. We appreciate it so much!

В данном подкасте мы обсудим роль таможенного брокера: от оформления к стратегии. Таможня и регулирующие агентства: CFIA, Health Canada, Transport Canada и др. Свободная торговля: преимущества соглашений с другими странами Торговые войны. Антидемпинговые и компенсационные меры (SIMA). Онлайн-покупки и e-commerce в 2025 году. Экспорт из Канады: когда требуется декларация, оформление B13A. Когда привлекать брокера: до покупки, при планировании и после прибытия груза. Есть ли разница откуда (из какой страны) импортировать для привлечения брокера. Приблизительная стоимость услуг брокера, как вообще устанавливается цена. Olexiy Tyshchenko, Licensed Customs Broker Ambassador Customs Brokerage Inc. Toll-Free: +1 (800) 962-8800 Cell: +1 (647) 870-5539, (613) 900-2322 Fax: +1 (833) 287-2238 Email: broker@ambassadorcustoms.ca Website: ambassadorcustoms.ca LinkedIn: linkedin.com/company/ambassador-customs-brokerage-inc (далее…) ————————————————- The content of this site and our podcasts are for information only. Everybody's financial situation is different and the thoughts we provide here may not be applicable to you. We can't be held responsible for the consequences if you pursue an unsuitable course of action. Сообщение Импорт в Канаду, что нужно знать импортёру! Новости 2025 и изменения с приходом Трампа | 304 появились сначала на Moneyinside.ca-самый популярный финансовый подкаст в Канаде!.

Send us a textThe Most Overlooked Risk in AI for Pathology? It's Not What You Think…Welcome, my trailblazing digital pathologists! In this episode, I dive headfirst into the regulatory maze of Artificial Intelligence (AI) in pathology, covering global frameworks, safety risks, ethics, and the future of software as a medical device. While regulation might not be the flashiest part of AI, ignoring it could cost us innovation—or worse, patient safety.We're on Part 5 of our 7-part AI in Pathology series, and this one's vital for anyone developing, using, or simply curious about AI and machine learning tools in healthcare.If you thought regulation was boring, think again—it's what separates a helpful algorithm from a dangerous black box.

In honor of International Day of the World's Indigenous Peoples on Aug 9, join host Dr. Cat Vendl for a special episode featuring two powerful Indigenous voices in health and healing. Meet Dr. Nicole Redvers, a member of the Deninu K'ue First Nation and Western Research Chair in Indigenous Planetary Health, who reveals how Indigenous healers have always treated humans and animals as interconnected beings. Then hear from Angaangaq, a traditional healer from Greenland whose spiritual mission is to "melt the ice in the heart of men."From Arctic seal hunting rituals that honor life to the simple power of saying "good morning," discover how Indigenous wisdom about balance, respect, and gratitude offers essential guidance for wildlife health professionals. A transformative conversation about breaking down silos, building bridges between knowledge systems, and remembering that healing begins with recognizing our interconnectedness with all life.LinksLearn more about Nicole's and Angaangaq's wisdom and work.We'd love to hear from you ... share your thoughts, feedback and ideas.

The newest wedge driving Canada and the U.S. apart? Skimmed milk powder, apparently. Like a straight-A high schooler whose grades drop at university, Health Canada is struggling with an increased workload.

Hundreds of homes on Vancouver Island are subject to an evacuation order due to a wildfire. New data looks into what professions may be driven to substance abuse. Israel's defence minister calls for the Israli takeover of Gaza. Health Canada recalling several brands of baby nest beds. Canadian teen Victoria Mboko has scored a stunning upset at the Canadian Open tennis tournament.

In this episode we sit down with Adam Foresman, co-founder and CEO of Ryden.ai, a groundbreaking startup that's redefining how MedTech companies approach compliance.After nearly two decades in quality and regulatory leadership—including roles at Dentsply, Midmark, and Vidya Health—Adam saw firsthand how overwhelming it had become to stay audit-ready across constantly shifting global regulations. So he built the tool he wished he had.Ryden.ai leverages AI to continuously scan a company's QMS, identify compliance gaps, and recommend updates based on global regulatory standards (FDA, ISO, EUMDR, Health Canada, and more). And it doesn't stop there—it's expanding to assess records, not just procedures, ensuring companies can demonstrate execution, not just intention.In this conversation, Adam shares:Why AI won't replace quality pros—but will make their jobs a lot easierThe biggest concerns companies have about using AI in GxP environments (and how Ryden addresses them)What the FDA's own shift to AI tools means for regulatory strategyHow both startups and enterprise MedTech teams are using Ryden to stay aheadA real-world win preparing a company for Health Canada with zero major findingsWhether you're a startup with limited resources or an enterprise with global sites to manage, Adam makes a compelling case: AI won't take your job—but it might save your sanity.Adam Foresman on LinkedIn: https://www.linkedin.com/in/adamforesman/Ryden.ai on the web: ryden.ai

Michelle Ferreri is a former Member of Parliament, entrepreneur, and media personality known for her unapologetic voice, bold opinions, and relentless drive to speak the truth. With over 26 years of experience in media and communications, Michelle has built a powerful personal brand that blends politics, purpose, and personality. A former Conservative MP for Peterborough—Kawartha, Michelle made history by flipping a bellwether riding and unseating a cabinet minister in 2021. During her time in Parliament, she served as Shadow Minister for Families, Children and Social Development and was a member of the committees on Human Resources and the Status of Women. Now, she's taking her mission beyond politics—empowering others through motivational speaking, digital content, and media storytelling that tackles the issues many are too afraid to touch. Whether it's standing up for victims, fighting for affordability, or challenging the status quo, Michelle brings courage, clarity, and conviction to every conversation.00:00 Introduction to the Political Landscape in Canada02:48 Michelle Ferreri's Journey into Politics06:01 Mental Health and Addiction Crisis09:06 Health Canada's Controversial Plans12:02 The State of Canadian Democracy15:07 The Role of Hope in Challenging Times17:55 The Power of the People21:09 Coping with the Current Political Climate30:56 The State of Canada: A Critical Analysis36:47 Ideology and Policy: The Underlying Issues39:45 The Importance of Conversation in Society45:29 Prison System Insights: A Disturbing Reality54:13 Concerns Over Child Safety in Prisons57:22 The Cost of Rehabilitation Programs01:00:15 Accountability in Government and Society01:02:51 The Impact of Apathy on Politics01:05:38 The Role of Communication in Politics01:08:45 Voting Dynamics in Canadian Politics01:11:47 The Future of Mental Health and Addiction Treatment01:17:25 Navigating Personal Struggles and Societal Boundaries01:19:45 The Power of Connection and Personal Gifts01:21:10 Overcoming Imposter Syndrome and Fear01:23:04 Challenging Addiction Treatment Paradigms01:27:00 The Role of Ibogaine in Addiction Recovery01:30:22 The Political Landscape and the Power of One01:33:39 Future Aspirations and Support for ChangeSubstack: https://substack.com/@kelsisheren - - - - - - - - - - - -SUPPORT OUR SPONSORS - - - - - - - - - - - -RHO Nutrition - Code: KELSI20 -  https://rhonutrition.com/KELSIXX-XY Athletics - Code: KELSI20 - https://www.xx-xyathletics.com/?sca_ref=7336247.FtJS2YUK4OKetone IQ- 30% off with code KELSI - https://ketone.com/KELSIGood Livin- 20% off with code KELSI - https://www.itsgoodlivin.com/?ref=KELSIBrass & Unity - 20% off with code UNITY - http://brassandunity.com - - - - - - - - - - - - -SHOPB&U Jewelry & Eyewear: https://brassandunity.com - - - - - - - - - - - - -Follow #thekelsisherenperspective- - - - - - - - - - - - -CHARITYHeroic Hearts Project - https://www.heroicheartsproject.orgAll Secure Foundation - http://allsecurefoundation.orgDefenders of Freedom -https://www.defendersoffreedom.usBoot Campaign - https://bootcampaign.org

The Public Health Agencies are created to deliver on the Government's commitment to help protect the health and safety of all people and communities in whatever country they live in.  For example: Canada's activities focus on: promoting health, well-being and equity protecting against threats to public health preventing and reducing diseases and injury Health Canada is responsible for helping Canadians maintain and improve their health. It ensures that high-quality health services are accessible, and works to reduce health risks. The UK supports ministers in leading the nation's health and social care to help people live more independent, healthier lives for longer. They are responsible for: supporting and advising their ministers: they help them shape and deliver policy that delivers the government's objectives setting direction: they anticipate the future and lead debate ensuring they protect and improve global and domestic health accountability: they make sure the department and their arm's length bodies deliver on their agreed plans and commitments acting as guardians of the health and care framework: they make sure the legislative, financial, administrative and policy frameworks are fit for purpose and work together troubleshooting: in the last resort, the public and Parliament expect them to take the action needed to resolve crucial and complex issues Although we at PodcastDX reside in the USA, due to recent administration changes we do not feel comfortable listing them as a resource at this time.

Did you know that most Canadians—and people in developed countries—are severely deficient in dietary fibre (or fiber, for our American friends)? In this eye-opening episode, Michelle and Kevin dive deep into the importance of fibre for digestive health, metabolism, weight management, and disease prevention. Discover the difference between soluble fibre and insoluble fibre, why prebiotic fibre and resistant starches are crucial for a healthy gut microbiome, and how inadequate fibre intake is linked to chronic illnesses like heart disease, type 2 diabetes, colon cancer, and more.Michelle explains why Health Canada's dietary fibre recommendations (28g for women, 35g for men) are just the bare minimum—and how easy it is to meet or exceed them with a whole food, plant-based diet. Learn practical tips for increasing your fibre intake through high-fibre foods like oats, beans, berries, flaxseed, vegetables, and legumes—without the bloat and gas that can come from doing it too quickly.You'll also hear about fascinating studies, including a prehistoric analysis showing ancient humans consumed up to 135 grams of fibre daily and modern hunter-gatherer societies who still thrive on fibre-rich diets. Plus, discover how fibre impacts satiety, gut health, blood sugar balance, and even cancer prevention.Whether you're plant-based, keto-curious, or somewhere in between, this episode will change the way you think about fibre—and your bathroom habits—for good.Stay in touch! Contact us at n4noobs@gmail.com or on Facebook at https://www.facebook.com/nutritionfornoobs. And don't forget to rate us on Apple Podcasts (or where ever you listen to us) and leave us a review - it really helps other listeners like you to find us. Thanks!

When avid outdoor adventurers Jaime Hackett and Erin Prohaska couldn't find a bug spray that actually worked and felt good on their skin, they decided to create their own. That's how Bite was born — a Toronto-based brand on a mission to make bug protection clean, non-toxic, and enjoyable to use.In this episode, the co-founders share the full story behind Bite's creation, from the personal frustrations that sparked their idea to the uphill climb of bringing a new kind of wellness product to market. We talk about what it takes to build a purpose-led brand in a highly regulated category, the red tape of Health Canada approvals, navigating a tough retail environment, and the steep learning curve of entrepreneurship in a product-based business. Jaime and Erin open up about the unexpected roadblocks, the grind of building something from the ground up, and the relentless belief that a better solution was possible.This is a conversation about the ups and downs of brand-building, and changing the way we think about the products we use every day — even bug spray.This season of our podcast is brought to you by TD Canada Women in Enterprise. TD is proud to support women entrepreneurs and help them achieve success and growth through its program of educational workshops, financing and mentorship opportunities! Please find out how you can benefit from their support! Visit: TBIF: thebrandisfemale.com // TD Women in Enterprise: td.com/ca/en/business-banking/small-business/women-in-business // Follow us on Instagram: instagram.com/thebrandisfemale

We talk about the excise tax and the changes needed, Ghost Drops is fighting Health Canada, a new lobbying group for cannabis, two people on every shift in Victoria cannabis stores and we stop on Cultivar Corner, brought to you by Up In Smoke, we sample from Rocky Mountain Cannabis their delicious sativa, Red Congolese.Cannabis lobbying groupNo solo staffing in VictoriaExcise needs to be fixedRocky Mountain Cannabis Red CongoleseGhost drops fights Health CanadaSome public fighting

What's in your drinking water? On Prince Edward Island, the provincial testing program shows potable water in some communities have higher levels of toxic “forever chemicals” than is recommended by Health Canada. To what extent this affects other provinces is unclear – PEI is currently the only province that systematically tests water supplies to make sure they hit federal targets for toxic chemicals.Patrick White is The Globe's water reporter. He explains the safety concerns surrounding “forever chemicals” in our water, why the health agency revamped its guidelines and looks into why other provinces are slow to adapt.Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

This episode of The Food Professor Podcast is steeped in insights, storytelling, and smoky Texas flavour. Hosts Michael LeBlanc and Dr. Sylvain Charlebois kick off with a deep dive into the state of Canadian agri-food policy, tariffs, and food inflation before welcoming a very special guest: Tonia Jahshan, Founder and CEO of Sipology.Broadcasting remotely from Texas, Sylvain shares updates from his new role as head of the prestigious Masters in Agribusiness program at Texas A&M University—ranked #1 in the U.S. and #3 globally. He offers behind-the-scenes insights into the world of American ag education, donor-funded infrastructure, and his leadership plans. Amidst meetings with deans and exploring campus, Sylvain visits a Texas institution of another kind—Buc-ee's, the legendary convenience store-meets-theme-park known for its brisket, wall of jerky, and award-winning bathrooms. The hosts revel in Buc-ee's cult status and then Michael highlights the newly released Texas Monthly Top 50 BBQ list, the Michelin Guide of Texas barbecue. Sylvain, a BBQ enthusiast, is already planning future brisket pilgrimages.  Congrats to our guest on the #pod from earlier this year Chuck Charnichart from Barb's BQ for making the list!!From Texas to Toronto, the episode pivots to policy with an analysis of Prime Minister Mark Carney's new mandate letter. Sylvain critiques its lack of clarity for the agri-food sector, calling for a shift from farm-gate thinking to value-chain strategy. The hosts then turn to the thorny issue of tea tariffs, which are hitting Canadian importers hard despite recent government reprieves. With tea being a $1.3 billion market in Canada—and nearly all of it imported—these tariffs are creating real cost pressures. The duo also revisits the long-running bread price-fixing investigation, discussing Loblaw's recent $500 million class action settlement and why the Competition Bureau's probe remains unresolved.In the second half of the episode, Tonia Jahshan joins the pod live from the SIAL Canada show floor. The inspirational founder of Sipology (formerly Steeped Tea) shares her origin story: how a single sip of loose-leaf Earl Grey in Nova Scotia after a miscarriage led to a wellness-focused tea empire. From launching a side hustle to pitching on Dragons' Den, growing to 8,000 consultants, and creating Health Canada-approved products like menopause relief teas and fizzy matchas, Tonia's entrepreneurial journey is one of resilience, reinvention, and remarkable growth. Now expanding globally and embracing an omni-channel model, she's brewing up a bold new future for Sipology.With a rich mix of policy insights, business strategy, entrepreneurial inspiration—and a side of Texas BBQ—this episode is a flavourful must-listen. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

MONOLOGUE Health Canada's Deadly Deception: Complicity in mRNA Vaccine Carnage NEWSMAKER Trump: Golden Dome will cost around $175B, be ‘fully operational' in three years https://defensescoop.com/2025/05/20/trump-golden-dome-cost-175-billion-fully-operational-three-years/   Douglas Ernest U.S. Army war veteran and entrepreneur. Author of The Spirit of a True Patriot: The Inspiring Story of Ret. Captain Douglas J. Ernest OPEN LINES THE SOFA CINEFILE Nick Soter reviews Back to the Future, the 1985 sci-fi family favourite starring Michael J. Fox and Christopher Lloyd THE LIMRIDDLER Folks at the TableFixture to fit all the folks at the table.Organ of nature to sunlight enable.Flip through a bookWith a cursory look.Emblem of ice hockey's frustrating fable. NEWSMAKER Israeli embassy staffers killed in Washington DC, suspect yelled ‘Free Palestine' https://www.westernstandard.news/international/israeli-embassy-staffers-killed-in-washington-dc-suspect-yelled-free-palestine/64932 Christopher Oldcorn is the Managing Editor of the Saskatchewan Standard. OPEN LINES NEWMAKER Canada can save the planet by feverishly pumping natural gas, report says https://nationalpost.com/opinion/first-reading-report-canada-save-planet-producing-lng  Dan McTeague, former longtime Liberal MP and President of Canadians for Affordable Energy affordable energy dot C-A. LIMRIDDLE ANSWER AND WINNERS The Answer to this week's Limriddle is: Leaf The first 5 to answer correctly were: 1. Christine De Civita, Stoney Creek, Ontario 2. Michael Dibblee, Vancouver, British Columbia 3. Amy Lou Hoo, East York, Ontario 4. Thomas LeBaron, Haliburton, Ontario 5. Joan- Marie Dibblee Markham, Ontario Fixture to fit all the folks at the table. A leaf is an extra section inserted into a dining table to increase seating capacity. There is no specific reference in the Bible to a leaf in the table at the Last Supper but Leonardo likely needed one so he could fit everybody in the painting. Organ of nature to sunlight enable. The leaf is considered an organ of a plant, performing the essential function of photosynthesis. Flip through a book With a cursory look. To leaf through a book is to casually flip the pages without paying much attention to content. Emblem of ice hockey's frustrating fable. The maple leaf is the emblem of the Toronto Maple Leafs, who last won the Stanley Cup in 1967. Technically, a fable is a short, fictional story with a moral. Sadly, the Leafs' story is none of these. Learn more about your ad choices. Visit megaphone.fm/adchoices

JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.” Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multigene panels compared with single-gene BRAF testing to guide therapeutic decisions in advanced melanoma. Transcript Dr. Rafeh Naqash:Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center in the University of Oklahoma. Today, we are excited to be joined by Dr. Dean A. Regier, Director at the Academy of Translational Medicine, Associate Professor at the School of Population and Public Health, UBC Senior Scientist at the British Columbia Cancer Research Institute, and also the senior author of the JCO Precision Oncology article entitled "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." At the time of this recording, our guest's disclosures will be linked in the transcript. Dean, welcome to our podcast and thank you for joining us today. Dr. Dean Regier:Thank you. I'm delighted to be here. Dr. Rafeh Naqash:So, obviously, you are from Canada, and medicine, or approvals of drugs to some extent, and in fact approvals of gene testing to some extent is slightly different, which we'll come to learn about more today, compared to what we do in the US—and in fact, similarly, Europe versus North America to a large extent as well. Most of the time, we end up talking about gene testing in lung cancer. There is a lot of data, a lot of papers around single-gene panel testing in non-small cell lung cancer versus multigene testing. In fact, a couple of those papers have been published in JCO PO, and it has shown significant cost-effectiveness and benefit and outcomes benefit in terms of multigene testing. So this is slightly, you know, on a similar approach, but in a different tumor type. So, could you tell us first why you wanted to investigate this question? What was the background to investigating this question? And given your expertise in health economics and policy, what are some of the aspects that one tends or should tend to understand in terms of cost-effectiveness before we go into the results for this very interesting manuscript? Dr. Dean Regier:Yeah, of course, delighted to. So, one of the reasons why we're deeply interested in looking at comparative outcomes with respect to single- versus multigene testing— whether that's in a public payer system like Canada or an insurer system, a private system in the United States— is that the question around does multigene versus single-gene testing work, has not typically tested in randomized controlled trials. You don't have people randomized to multigene versus single-gene testing. And what that does, it makes the resulting evidence base, whether it's efficacy, safety, or comparative cost-effectiveness, highly uncertain. So, the consequence of that has been uneven uptake around the world of next-generation sequencing panels. And so if we believe that next-gen sequencing panels are indeed effective for our patients, we really need to generate that comparative evidence around effectiveness and cost-effectiveness. So we can go to payers, whether it be single payer or a private insurer, to say, "Here are the comparative outcomes." And when I say that uptake has been uneven, uptake there's been actually plenty, as you know, publications around that uneven uptake, whether it be in Europe, in the United States, in Canada. And so we're really interested in trying to produce that evidence to create the type of deliberations that are needed to have these types of technologies accessible to patients. And part of those deliberations, of course, is the clinical, but also in some contexts, cost-effectiveness. And so, we really start from the perspective of, can we use our healthcare system data, our learning healthcare system, to generate that evidence in a way that emulates a randomized controlled trial? We won't be able to do these randomized controlled trials for various, like really important and and reasons that make sense, quite frankly. So how can we mimic or emulate randomized controlled trials in a way that allows us to make inference around those outcomes? And for my research lab, we usually think through how do we do causal inference to address some of those biases that are inherent in observational data. So in terms of advanced melanoma, we were really interested in this question because first of all, there have been no randomized controlled trials around next-gen sequencing versus single-gene testing. And secondly, these products, these ICIs, immune checkpoint inhibitors, and BRAF and MEK inhibitors, they are quite expensive. And so the question really becomes: are they effective? And if so, to what extent are they cost-effective? Do they provide a good reason to have information around value for money? Dr. Rafeh Naqash:So now going to the biology of melanoma, so we know that BRAF is one of the tumor-agnostic therapies, it has approvals for melanoma as well as several other tumor types. And in fact, I do trials with different RAF-RAS kinase inhibitors. Now, one of the things that I do know is, and I'm sure some of the listeners know, is the DREAMseq trial, which was a melanoma study that was an NCI Cooperative Group trial that was led by Dr. Mike Atkins from Georgetown a couple of years back, that did show survival benefit of first-line immunotherapy sequencing. It was a sequencing study of whether to do first-line BRAF in BRAF-mutant melanoma followed by checkpoint inhibitors, or vice versa. And the immune checkpoint inhibitors followed by BRAF was actually the one that showed benefit, and the trial had to stop early, was stopped early because of the significant benefit seen. So in that context, before we approach the question of single-gene versus multigene testing in melanoma, one would imagine that it's already established that upfront nivolumab plus ipilimumab, for that matter, doublet checkpoint inhibitor therapy is better for BRAF-mutant melanoma. And then there's no significant other approvals for melanoma for NRAS or KIT, you know, mucosal melanomas tend to have KIT mutations, for example, or uveal melanomas, for that matter, have GNAQ, and there's no targeted therapies. So, what is the actual need of doing a broader testing versus just testing for BRAF? So just trying to understand when you started looking into this question, I'm sure you kind of thought about some of these concepts before you delved into that. Dr. Dean Regier:I think that is an excellent question, and it is a question that we asked ourselves: did we really expect any differences in outcomes between the testing strategies? And what did the real-world implementation, physician-guided, physician-led implementation look like? And so, that was kind of one of the other reasons that we really were interested is, why would we go to expanded multigene panel sequencing at all? We didn't really expect or I didn't expect an overall survival a priori. But what we saw in our healthcare system, what happened in our healthcare system was the implementation in 2016 of this multigene panel. And this panel covered advanced melanoma, and this panel cost quite a bit more than what they were doing in terms of the single-gene BRAF testing. And so when you're a healthcare system, you have to ask yourself those questions of what is the additional value associated with that? And indeed, I think in a healthcare system, we have to be really aware that we do not actually follow to the ideal extent randomized controlled trials or trial settings. And so that's the other thing that we have to keep in mind is when these, whether it's an ICI or a BRAF MEK inhibitor, when these are implemented, they do not look like randomized controlled trials. And so, we really wanted to emulate not just a randomized controlled trial, but a pragmatic randomized controlled trial to really answer those real-world questions around implementation that are so important to decision making. Dr. Rafeh Naqash:Sure. And just to understand this a little better: for us in the United States, when we talk about multigene testing, we generally refer to, these days, whole-exome sequencing with whole-transcriptome sequencing, which is like the nuclear option of of the testings, which is not necessarily cheap. So, when you talk about multigene testing in your healthcare system, what does that look like? Is it a 16-gene panel? Is it a 52-gene panel? What is the actual makeup of that platform? Dr. Dean Regier:Excellent question. Yeah, so at the time that this study is looking at, it was 2016, when we, as BC Cancer—so British Columbia is a population right now of 5.7 million people, and we have data on all those individuals. We are one healthcare system providing health care to 5.7 million people. In 2016, we had what I call our "home-brew" multigene panel, which was a 53-gene panel that was reimbursed as standard of care across advanced cancers, one of them being advanced melanoma. We have evolved since then. I believe in 2022, we are using one of the Illumina panels, the Focus panel. And so things have changed; it's an evolving landscape. But we're specifically focused on the 53-gene panel. It was called OncoPanel. And that was produced in British Columbia through the Genome Sciences Centre, and it was validated in a single-arm trial mostly around validity, etc. Dr. Rafeh Naqash:Thank you for explaining that. So now, onto the actual meat and the science of this project. So, what are some of the metrics from a health economy standpoint that you did look at? And then, methodology-wise, I understand, in the United States, we have a fragmented healthcare system. I have data only from my institution, for that matter. So we have to reach out to outside collaborators and email them to get the data. And that is different for you where you have access to all the data under one umbrella. So could you speak to that a little bit and how that's an advantage for this kind of research especially? Dr. Dean Regier:Yeah. In health economics, we look at the comparative incremental costs against the incremental effectiveness. And when we think about incremental costs, we think not just about systemic therapy or whether you see a physician, but also about hospitalizations, about all the healthcare interactions related to oncology or not that a patient might experience during their time or interactions with the healthcare system. You can imagine with oncology, there are multiple interactions over a prolonged time period depending on survival. And so what we try to do is we try to—and the benefit of the single-payer healthcare system is what we do is we link all those resource utilization patterns that each patient encounters, and we know the price of that encounter. And we compare those incremental costs of, in this case, it's the multigene panel versus the single-gene panel. So it's not just the cost of the panel, not just the cost of systemic therapy, but hospitalizations, physician encounters, etc. And then similarly, we look at, in this case, we looked at overall survival - we can also look at progression-free survival - and ask the simple question, you know, what is the incremental cost per life-year gained? And in that way, we get a metric or an understanding of value for money. And how we evaluate that within a deliberative priority setting context is we look at safety and efficacy first. So a regulatory package that you might get from, in our case, Health Canada or the FDA, so we look at that package, and we deliberate on, okay, is it safe and is it effective? How many patients are affected, etc. And then separately, what is the cost-effectiveness? And at what price, if it's not cost-effective, at what price would it be cost-effective? Okay, so for example, we have this metric called the incremental cost-effectiveness ratio, which is incremental cost in the numerator, and in this case, life-years gained in the denominator. And if it is around $50,000 or $100,000 per life-year gained—so if it's in that range, this ratio—then we might say it's cost-effective. If it's above this range, which is common in oncology, especially when we talk about ICIs, etc., then you might want to negotiate a price. And indeed, when we negotiate that price, we use the economic evaluation, that incremental cost-effectiveness ratio, as a way to understand at what price should we negotiate to in order to get value for money for the healthcare system. Dr. Rafeh Naqash:Thank you for explaining those very interesting terminologies. Now, one question I have in the context of what you just mentioned is, you know, like the drug development space, you talked about efficacy and safety, but then on the safety side, we talk about all-grade adverse events or treatment-related adverse events—two different terminologies. From a healthcare utilization perspective, how do you untangle if a patient on a BRAF therapy got admitted for a hypoxic respiratory failure due to COPD, resulting in a hospitalization from the cost, overall cost utilization, or does it not matter? Dr. Dean Regier:We try to do as much digging into those questions as possible. And so, this is real-world data, right? Real-world data is not exactly as clean as you'd get from a well-conducted clinical trial. And so what we do is we look at potential adverse event, whether it's hospitalization, and the types of therapies around that hospitalization to try- and then engage with clinicians to try to understand or tease out the different grades of the adverse event. Whether it's successful or not, I think that is a real question that we grapple with in terms of are we accurate in delineating different levels of adverse events? But we try to take the data around the event to try to understand the context in which it happens. Dr. Rafeh Naqash:Thank you for explaining that, Dean. So, again to the results of this manuscript, could you go into the methodology briefly? Believe you had 147 patients, 147 patients in one arm, 147 in the other. How did you split that cohort, and what were some of the characteristics of this cohort? Dr. Dean Regier:So, the idea, of course, is that we have selection criteria, study inclusion criteria, which included in our case 364 patients. And these were patients who had advanced melanoma within our study time period. So that was 2016 to 2018. And we had one additional year follow. So we had three total years. And what we did is that we linked our data, our healthcare system data. During this time, because the policy change was in 2016, we had patients both go on the multigene panel and on the single-gene BRAF testing. So, the idea was to emulate a pragmatic randomized controlled trial where we looked at contemporaneous patients who had multigene panel testing versus single-gene BRAF testing. And then we did a matching procedure—we call it genetic matching. And that is a type of matching that allows us to balance covariates across the patient groups, across the multigene versus BRAF testing cohorts. The idea again is, as you get in a randomized controlled trial, you have these baseline characteristics that look the same. And then the hope is that you address any source selection or confounding biases that prohibit you to have a clean answer to the question: Is it effective or cost-effective? So you address all those biases that may prohibit you to find a signal if indeed a signal is there. And so, what we did is we created—we did this genetic matching to balance covariates across the two cohorts, and we matched them one-to-one. And so what we were able to do is we were able to find, of those 364 patients in our pool, 147 in the multigene versus 147 in the single-gene BRAF testing that were very, very similar. In fact, we created what's called a directed acyclic graph or a DAG, together with clinicians to say, “Hey, what biases would you expect to have in these two cohorts that might limit our ability to find a signal of effectiveness?” And so we worked with clinicians, with health economists, with epidemiologists to really understand those different biases at play. And the genetic matching was able to match the cohorts on the covariates of interest. Dr. Rafeh Naqash:And then could you speak on some of the highlights from the results? I know you did survival analysis, cost-effectiveness, could you explain that in terms of what you found? Dr. Dean Regier:We did two analyses. The intention-to-treat analysis is meant to emulate the pragmatic randomized controlled trial. And what that does is it answers the question, for all those eligible for multigene or single-gene testing: What is the cost-effectiveness in terms of incremental life-years gained and incremental cost per life-years gained? And the second one was around a protocol analysis, which really answered the question of: For those patients who were actually treated, what was the incremental effectiveness and cost-effectiveness? Now, they're different in two very important ways. For the intention-to-treat, it's around population questions. If we gave single-gene or multigene to the entire population of advanced melanoma patients, what is the cost-effectiveness? The per-protocol is really around that clinical question of those who actually received treatment, what was the incremental cost and effectiveness? So very different questions in terms of population versus clinical cost and effectiveness. So, for the intention-to-treat, what we found is that in terms of life-years gained is around 0.22, which is around 2.5 months of additional life that is afforded to patients who went through the multigene panel testing versus the single-gene testing. That was non-statistically significant from zero at the 5% level. But on average, you would expect this additional 2.5 months of life. The incremental costs were again non-statistically significant, but they're around $20,000. And so when we look at incremental cost-effectiveness, we can also look at the uncertainty around that question, meaning what percentage of incremental cost-effectiveness estimates are likely to be cost-effective at different willingness-to-pay thresholds? Okay? So if you are willing to pay $100,000 to get one gain of life-years, around 52.8% of our estimates, in terms of when we looked at the entire uncertainty, would be cost-effective. So actually that meets the threshold of implementation in our healthcare system. So it's quite uncertain, just over 50%. But what we see is that decision-makers actually have a high tolerance for uncertainty around cost-effectiveness. And so, while it is uncertain, we would say that, well, the cost-effectiveness is finely balanced. Now, when we looked at the population, the per-protocol population, those folks who just got treatment, we actually have a different story. We have all of a sudden around 4.5 or just under 5 months of life gained that is statistically significantly different from zero, meaning that this is a strong signal of benefit in terms of life-years gained. In terms of the changes in costs or the incremental costs, they are larger again, but statistically insignificant. So the question now is, to what extent is it cost-effective? What is the probability of it being cost-effective? And at the $100,000 per life-year gained willingness-to-pay, there was a 73% chance that multigene panel testing versus single-gene testing is cost-effective. Dr. Rafeh Naqash:So one of the questions I have here, this is a clarification both for myself and maybe the listeners also. So protocol treatment is basically if you had gene testing and you have a BRAF in the multigene panel, then the patient went on a BRAF treatment. Is that correct? Dr. Dean Regier:It's still physician choice. And I think that's important to say that. So typically what we saw in both in our pre- and post-matching data is that we saw around 50% of patients, irrespective of BRAF status, get an ICI, which is appropriate, right? And so the idea here is that you get physician-guided care, but if the patient no longer performs on the ICI, then it gives them a little bit more information on what to do next. Even during that time when we thought it wasn't going to be common to do an ICI, but it was actually quite common. Dr. Rafeh Naqash:Now, did you have any patients in this study who had the multigene testing done and had an NRAS or a KIT mutation and then went on to those therapies, which were not captured obviously in the single-gene testing, which would have just tried to look at BRAF? Dr. Dean Regier:So I did look at the data this morning because I thought that might come up in terms of my own questions that I had. I couldn't find it, but what we did see is that some patients went on to clinical trials. So, meaning that this multigene panel testing allowed, as you would hope in a learning healthcare system, patients to move on to clinical trials to have a better chance at more appropriate care if a target therapy was available. Dr. Rafeh Naqash:And the other question in that context, which is not necessarily related to the gene platform, but more on the variant allele frequency, so if you had a multigene panel that captured something that was present at a high VAF, with suspicion that this could be germline, did you have any of those patients? I'm guessing if you did, probably very low number, but I'm just thinking from a cost-effective standpoint, if you identify somebody with germline, their, you know, first-degree relative gets tested, that ends up, you know, prevention, etc. rather than somebody actually developing cancer subsequently. That's a lot of financial gains to the system if you capture something early. So did you look at that or maybe you're planning to look at that? Dr. Dean Regier:We did not look at that, but that is a really important question that typically goes unanswered in economic evaluations. And so, the short answer is yes, that result, if there was a germline finding, would be returned to the patient, and then the family would be able to be eligible for screening in the appropriate context. What we have found in economic evaluations, and we've recently published this research, is that that scope of analysis is rarely incorporated into the economic evaluation. So those downstream costs and those downstream benefits are ignored. And when you- especially also when you think about things like secondary or incidental findings, right? So it could be a germline finding for cancer, but what about all those other findings that we might have if you go with an exome or if you go with a genome, which by the way, we do have in British Columbia—we do whole-genome and transcriptome sequencing through something called the Personalized OncoGenomics program. That scope of evaluation, because it's very hard to get the right types of data, because it requires a decision model over the lifetime of both the patients and potentially their family, it becomes very complicated or complex to model over patients' and families' lifetime. That doesn't mean that we should not do it, however. Dr. Rafeh Naqash:So, in summary Dean, could you summarize some of the known and unknowns of what you learned and what you're planning in subsequent steps to this project? Dr. Dean Regier:Our North Star, if you will, is to really understand the entire system effect of next-generation sequencing panels, exome sequencing, whole genomes, or whole genomes and transcriptome analysis, which we think should be the future of precision oncology. The next steps in our research is to provide a nice base around multigene panels in terms of multigene versus single-gene testing, whether that be colorectal cancer, lung cancer, melanoma, etc., and to map out the entire system implications of implementing next-generation sequencing panels. And then we want to answer the questions around, “Well, what if we do exomes for all patients? What if we do whole genomes and transcriptomes for all patients? What are the comparative outcomes for a true tumor-agnostic precision oncology approach, accounting for, as you say, things like return of results with respect to hereditary cancers?” I think the challenge that's going to be encountered is really around the persistent high costs of something like a whole-genome and transcriptome sequencing approach. Although we do see the technology prices going down—the "$1,000 genome" or “$6,000 genome" on whatever Illumina machine you might have—that bioinformatics is continuing to be expensive. And so, there are pipelines that are automated, of course, and you can create a targeted gene report really rapidly within a reasonable turnaround time. But of course, for secondary or what I call level two analysis, that bioinformatics is going to continue to be expensive. And so, we're just continually asking that question is: In our healthcare system and in other healthcare systems, if you want to take a precision oncology approach, how do you create the pipelines? And what types of technologies really lend themselves to benefits over and above next-generation sequencing or multigene panels, allowing for access to off-label therapies? What does that look like? Does that actually improve patients? I think some of the challenges, of course, is because of heterogeneity, small benefiting populations, finding a signal if a signal is indeed there is really challenging. And so, what we are thinking through is, with respect to real-world evidence methods and emulating randomized controlled trials, what types of evidence methods actually allow us to find those signals if indeed those signals are there in the context of small benefiting populations? Dr. Rafeh Naqash:Thank you so much, Dean. Sounds like a very exciting field, especially in the current day and age where cost-effectiveness, financial toxicity is an important aspect of how we improve upon what is existing in oncology. And then lots more to be explored, as you mentioned. The last minute and a half I want to ask about you as an individual, as a researcher. There's very few people who have expertise in oncology, biomarkers, and health economics. So could you tell us for the sake of our trainees and early career physicians who might be listening, what was your trajectory briefly? How did you end up doing what you're doing? And maybe some advice for people who are interested in the cost of care, the cost of oncology drugs - what would your advice be for them very briefly? Dr. Dean Regier:Sure. So I'm an economist by training, and indeed I knew very little about the healthcare system and how it works. But I was recruited at one point to BC Cancer, to British Columbia, to really try to understand some of those questions around costs, and then I learned also around cost-effectiveness. And so, I did training in Scotland to understand patient preferences and patient values around quality of care, not just quantity of life, but also their quality of life and how that care was provided to them. And then after that, I was at Oxford University at the Nuffield Department of Population Health to understand how that can be incorporated into randomized control trials in children. And so, I did a little bit of learning about RCTs. Of course, during the way I picked up some epidemiology with deep understanding of what I call econometrics, what others might call biostatistics or just statistics. And from there, it was about working with clinicians, working with epidemiologists, working with clinical trialists, working with economists to understand the different approaches or ways of thinking of how to estimate efficacy, effectiveness, safety, and cost-effectiveness. I think this is really important to think through is that we have clinical trialists, we have people with deep understanding of biostatistics, we have genome scientists, we have clinicians, and then you add economists into the mix. What I've really benefited from is that interdisciplinary experience, meaning that when I talk to some of the world's leading genome scientists, I understand where they're coming from, what their hope and vision is. And they start to understand where I'm coming from and some of the tools that I use to understand comparative effectiveness and cost-effectiveness. And then we work together to actually change our methods in order to answer those questions that we're passionate about and curious about better for the benefit of patients. So, the short answer is it's been actually quite a trajectory between Canada, the UK. I spent some time at the University of Washington looking at the Fred Hutch Cancer Research Center, looking at precision oncology. And along the way, it's been an experience about interdisciplinary research approaches to evaluating comparative outcomes. And also really thinking through not just at one point in time on-off decisions—is this effective? Is it safe? Is it cost-effective?—not those on-off decisions, but those decisions across the lifecycle of a health product. What do those look like at each point in time? Because we gain new evidence, new information at each point in time as patients have more and more experience around it. And so what really is kind of driving our research is really thinking about interdisciplinary approaches to lifecycle evaluation of promising new drugs with the goal of having these promising technologies to patients sooner in a way that is sustainable for the healthcare system. Dr. Rafeh Naqash:Awesome. Thank you so much for those insights and also giving us a sneak peek of your very successful career. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Are you new to the medical device industry—or mentoring someone who is? In this foundational episode of the Global Medical Device Podcast, host Etienne Nichols sits down with Sara Adams and Chris Rush from Greenlight Guru to deliver a MedTech 101 masterclass. They unpack the roles, regulations, and realities of medical device development in a heavily regulated space. From defining what actually counts as a medical device to navigating FDA classifications and global regulations, the trio offers practical insights, industry analogies, and personal war stories that make this episode as entertaining as it is educational. Whether you're in R&D, marketing, clinical, or quality, this is the episode to bookmark and share with every new hire.Key Timestamps02:20 – What counts as a medical device? Intended use and labeling06:48 – Differentiating roles: Quality, Regulatory, Clinical, R&D, and Marketing15:40 – Understanding regulatory bodies: FDA, EU MDR, Health Canada, and more20:15 – FDA Classifications: Class I, II, III, and what determines risk26:00 – Standards to know: ISO 13485, 14971, 14155, 21 CFR Part 82033:05 – FDA pathways: 510(k), De Novo, PMA – when and why they apply41:55 – The design control matrix explained (User Needs through Validation)49:00 – Reverse engineering design controls: pitfalls and best practices55:30 – Clinical trials vs. preclinical studies: When each is required1:00:45 – Manufacturing & supplier controls: operations meets compliance1:04:15 – Final advice for MedTech newcomers: Read the regs and know the problemQuotes“Just because you don't call it a medical device doesn't mean the FDA agrees with you.” – Sarah AdamsThis quote highlights a key regulatory pitfall: your marketing claims, not just your label, determine if the FDA considers your product a medical device.“A 510(k) is like someone checking your wristband at the door—you're cleared to go in. A PMA? That's a locked door and you need full approval to enter.” – Chris RushA memorable analogy that demystifies the difference between FDA clearance and approval pathways.Top TakeawaysLabeling + Intended Use = Regulatory TriggerWhether it's software or a simple tool, if your product makes medical claims or supports medical decision-making, it may fall under FDA or other international regulatory oversight.Regulatory Pathways Are Tied to Risk and NoveltyKnow the difference between a 510(k), De Novo, and PMA. Class II “me-too” devices may avoid clinical trials, while Class III and novel devices usually require significant evidence.Understand Design Controls EarlyReverse-engineering documentation late in development is risky and inefficient. Start early with user needs and build forward through the five pillars: inputs, outputs, verification, and validation.Cross-functional Understanding Prevents Compliance GapsMarketing, clinical, and R&D all influence regulatory standing. Even social media likes can trigger off-label scrutiny—every department needs to understand their regulatory impact.Reading Regulations Is Not OptionalA strong regulatory foundation is key to faster development, better audits, and smoother market access. Resources like 21 CFR Part 820 and ISO 13485 are surprisingly readable and essential.References & ResourcesEtienne Nichols on LinkedInChris Rush on LinkedIn

I have a special in-house interview today with 2 men currently on a mission across Canada sharing the truth about a story of a family and their plight to help those suffering with mental illness and about the nightmare this family had to endure for years.Todd Michael Harris and David Stephan are on tour promoting the film 'Epiphany' and David's harrowing journey. The interview delves deeply into David's family's struggles with mental health, their pioneering work in nutritional supplements, and an intense legal battle with the Canadian health system.They discuss the transformative power of their line supplements, aptly named True Hope, the dynamics behind David's wrongful conviction, the death of his son Ezekiel, and how media and health authorities continue to misrepresent their story despite clear proof otherwise.This is a story of resilience and highlights the corruption among organizations we look to for justice, truth and support. Instead of finding any of these things, the Stephans were met with corruption at every step that started over 20 years ago.Please go to Matadorfilms.ca to see if this film and discussion is coming to your city in the next few weeks. This is a story that needs to be told, heard and shared.01:00 Introducing Today's Special Guests: Todd Michael Harris and David Stephan01:29 The Tragic Story of David Stephan's Family03:48 Todd's Journey in Filmmaking06:03 David's Family History and Struggles with Mental Health15:13 The Birth of True Hope and Nutritional Discoveries28:56 The Impact of Health Canada and Legal Battles34:13 The Fight for Truth and Justice37:51 The Power of Justice and Identity38:26 Reaching Beyond the Choir38:41 Challenges in Spreading the Truth39:01 Audience Reactions and Support41:25 The Birth of True Hope Empire Plus43:23 Health Canada's Contradictions44:13 Justice and Truth: An Interdependent Relationship45:22 Media's Role in Shaping Public Perception47:40 Medical Misadventures and Systemic Issues49:47 The Fight for Natural Health Products50:56 Legal Battles and Personal Struggles52:25 The Aftermath and Seeking Justice56:05 Systemic Corruption and Cover-Ups01:04:44 Exposing the Truth and Seeking Accountability01:07:25 Personal Connections and Accountability01:07:55 The Illusion of Trust in Systems01:08:48 Facing Challenges and Integrity01:09:25 The Plea Bargain Dilemma01:11:40 Tour Goals and Media Coverage01:17:43 Nutritional Products and Their Benefits01:25:05 Protocols and Health Canada Restrictions01:30:33 Final Thoughts and Call to ActionPlease share this interview, the world needs to know the truth about the nightmare this family has experienced at the hands of authorities that people wrongfully trust.If you enjoyed this episode, please share and consider going to www.sovereigncollective.org/shop to check out my offerings and get a deal while supporting the podcast. I'll be adding more great offerings there over time.To find out more about David Stephan and True Hope:Website: https://www.truehope.com/Facebook: https://www.facebook.com/david.stephan.568Instagram: https://www.instagram.com/stand4truth.ca/To find out more about the films of Todd Michael Harris:https://matadorfilms.ca/Please like and subscribe wherever you listen... it all helps and I appreciate it with my whole heart!----------------------------------------------------------Are you concerned about the future of our children?The world needs more conscious parents. Stop raising children who need to recover from their childhoods! Get your online program chock full of interviews with world renowned experts here:http://www.sovereigncollective.org/gettheguideEmail me: sascha at sovereigncollective dot org

Dr. Mark Ware joins Chris to discuss the state of the science for medical cannabis. Why should we be calling it cannabis and not marijuana? What are the challenges of studying something that is still illegal in the United States? How good is it at treating chronic pain and which of its health claims are mainly hype?  Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information.

Some people struggling with opioid addiction are turning to a powerful psychedelic called ibogaine. The drug is derived from the bark of an African rainforest shrub, and its proponents believe it sends people on a transformative journey that can free them from addiction. In countries like Mexico, ibogaine use is unregulated, so resort-like clinics are offering what they consider treatment for addiction, by sending people on powerful psychedelic trips. In her documentary "Ibogaine: The Last Trip?", senior CBC reporter Karen Pauls introduces us to Rocky Dhillon. He's one of a growing number of Canadians who are seeking out this treatment in Mexico. We'll also meet a Winnipeg businessman who is trying to get Health Canada approval for clinical trials of ibogaine, with the goal of offering it as a treatment for addiction in Canada. Some say the drug has changed their lives but there have also been tragic consequences, like the Canadian man who died on an ibogaine trip in South Africa. Produced by Karen Pauls and Joan Webber / originally aired on The Current. Storylines is part of the CBC Audio Doc Unit

Episode 201 – we look at how we grew cannabis outdoors – the new regulations from Health Canada our out and we have a window to your weed.  We stop on Cultivar Corner, brought to you by Up In Smoke, we tastes the duo for the live rosin, Purfefire Grape Slurpee and Critical Condition.   All of that more on episode 201 of the Cannabis Potcast.Outdoor cannabisHealth Canada UpdatePurefire Grape Slurpee and Critical Condition

I was very proud to use the word “apotheosis” on today's podcast.  See if you can pick out the moment.  I say something like, “Palliative care for people experiencing homelessness is, in many ways, the apotheosis of great palliative care.”  And I believe that to be true.  When you think about the early concepts that shaped the field, you can see how palliative care for persons experiencing homelessness fits like a hand in a glove: total pain envisioned by Cicely Saunders, which even its earliest sketches included social suffering like loneliness; or Balfour Mount, who coined the term “palliative care,” lamenting the cruel irony of our care for the dying, and the desperate need to create programs to reach more people experiencing suffering. Today we talk with Naheed Dosani, a palliative care physician at St. Michael's Hospital in Toronto, and health justice activist. His story, which he shares on today's podcast, is remarkable.  Just out of fellowship, Naheed built a palliative care program for homeless persons  called the Palliative Education and Care for the Homeless (PEACH) Program.  This podcast is a complement to our prior podcast on aging and homelessness with Margot Kushel. Today we discuss: What is the best terminology? Homeless? Homelessness? Houseless? Marginally housed? What makes palliative care for people experiencing homelessness challenging? What makes it rewarding?  What is unique about the practice of palliative care for people experiencing homelessness? We discuss the principles of harm reduction, social determinants of health, and trauma informed care.  Major overlap with substance use disorder issues, which we have covered recently (and frequently) on this podcast. How are the health systems designed or not designed to meet the needs of people experiencing homelessness?  What are the equity issues at stake, and at risk of being cut, both in Canada and the US?   Many more links below.  And I had a blast playing Blinding Lights by that Toronto band The Weekend. Enjoy! -Alex   End Well Talk https://www.youtube.com/watch?v=eG4QE-hfPQU Resources on the PEACH Program Program Review Paper – A recent publication in Longwoods Healthcare Quarterly reviewing the PEACH model. https://pubmed.ncbi.nlm.nih.gov/37144698/ Promising Practice Recognition – PEACH was named a Promising Practice in equity-oriented palliative care as part of a national initiative funded by Health Canada, operated by Healthcare Excellence Canada & the Canadian Partnership Against Cancer. https://www.healthcareexcellence.ca/media/z3jifqqd/pp-peach-en-2024-v2.pdf Toronto Star Feature https://www.thestar.com/life/together/people/dr-naheed-dosani-started-peach-to-provide-palliative-care-for-homeless-and-vulnerably-housed-populations/article_c56d8f45-cbe9-522e-9554-46778bf50407.html CityNews Toronto Feature https://toronto.citynews.ca/2022/08/08/peach-team-palliative-health-care-homelessness/ Psychosocial Interventions at PEACH In addition to medical care, PEACH also runs two key psychosocial interventions for our clients: PEACH Grief Circles – Structured spaces for workers in the homelessness sector to process grief. CBC covered this a few years ago, including a radio segment feature on CBC White Coat, Black Art (which you can access at the below link). https://www.cbc.ca/radio/whitecoat/palliative-care-team-helps-the-homeless-die-with-dignity-a-healing-circle-helps-them-grieve-1.5048409 PEACH Good Wishes Program – A program that provides meaningful gifts for unhoused individuals who are terminally ill. https://www.cbc.ca/news/canada/toronto/toronto-homeless-palliative-holidays-1.5407360 Kensington Hospice & 'Radical Love' Equity-Oriented Hospice Palliative Care Naheed Dosani also serves as the Medical Director of Kensington Hospice, Toronto's largest hospice. There, he helps run an innovative program called 'Radical Love' Equity-Oriented Hospice Palliative Care, which provides low-threshold, low-barrier access to hospice care for structurally vulnerable individuals (e.g., those experiencing homelessness). The program also operates via a partnership with the PEACH Program. As a result of the 'Radical Love' program at Kensington Hospice: At any given time, Kensington Hospice has evolved from caring for structurally vulnerable individuals